Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx (Euronext & Nasdaq: ARGX) announced that CEO Karen Massey will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.
A live webcast will be available at argenx.com/investors, with a replay accessible on the company website for approximately 30 days after the presentation.
argenx (Euronext & Nasdaq: ARGX) announced board changes following its Annual General Meeting on May 6, 2026. Karen Massey was appointed Chief Executive Officer and executive director for a four-year term, while co-founder Tim Van Hauwermeiren becomes Chairperson and non-executive director.
Shareholder turnout was 90.9% and all agenda items passed, including a shareholder authorization to issue shares or subscription rights up to 10% of outstanding capital for 18 months.
argenx (Euronext & Nasdaq: ARGX) will report its first quarter 2026 financial results and host a business update on May 7, 2026 at 2:30 PM CET / 8:30 AM ET. The company will hold a conference call and audio webcast for investors and analysts.
A live webcast is available at the Investors section of argenx.com/investors and a replay will remain accessible for approximately one year. Dial-in access numbers and access code 3810049 are provided; participants are asked to dial in 15 minutes early.
argenx (Nasdaq: ARGX) presented new VYVGART data at AAN 2026 showing expanded efficacy across myasthenia gravis (MG) subtypes and CIDP. ADAPT OCULUS met its primary endpoint (p=0.012) in ocular MG; sBLAs for oMG and broader gMG populations have regulatory submissions in progress, including a priority review target action date of May 10, 2026.
ADHERE post hoc and real-world data support early benefit and IVIg-to-Hytrulo switching in CIDP, and pediatric/adolescent ADAPT Jr results show durable symptom gains.
argenx (Euronext & Nasdaq: ARGX) announced its Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol.
Agenda items include adoption of the 2025 annual accounts, advisory vote on the 2025 remuneration report, discharge of directors, share issuance authorization and several board appointments and reappointments. Documents and e-voting information are available on the argenx website and via ABN AMRO e-voting; shareholders are encouraged to vote by proxy. For copies contact legal@argenx.com.
argenx (NASDAQ: ARGX) will present clinical and real-world data for VYVGART and pipeline candidates at the 2026 AAN Annual Meeting (April 18–22, 2026) in Chicago.
Highlights include positive Phase 3 ADAPT OCULUS results in ocular myasthenia gravis, ADAPT SERON data showing efficacy in AChR‑Ab–negative gMG subtypes, CIDP biomarker and ADHERE analyses, and ARGX‑119 Phase 1b safety and functional improvements.
argenx (NASDAQ:ARGX) reported strong 2025 results: $4.2 billion in full‑year product net sales (≈+90% YoY) and ~$1.1 billion operating income, its first profitable year on an operating basis. The company announced positive ADAPT OCULUS oMG data and a PDUFA target date of May 10, 2026 for seronegative gMG.
argenx reiterated Vision 2030 goals, growth plans for the VYVGART franchise, multiple upcoming registrational readouts through 2026–2027, and expansion of its FcRn and broader immunology pipeline.
argenx (NASDAQ:ARGX) reported positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis (oMG) on February 26, 2026. The study met its primary endpoint (p=0.012) with a mean MGII PRO ocular score improvement of 4.04 for VYVGART vs 1.99 for placebo at Week 4.
Patients showed marked reductions in diplopia and ptosis; safety was consistent with prior studies and no new concerns were identified. Results support a planned sBLA submission to the FDA to expand the VYVGART label into oMG.
argenx (Euronext & Nasdaq: ARGX) announced that Karen Massey, Chief Operating Officer, will speak in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 11:50 a.m. ET.
According to the company, a live webcast will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days after the presentation.
argenx (NASDAQ:ARGX) will report full year 2025 financial results and deliver a fourth quarter business update on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET).
The company said a live audio webcast and conference call will be available via the Investors section at argenx.com/investors, with a replay available for about one year. Dial-in access code: 3810049.